Quintiles invests in cancer biomarker start-up
This article was originally published in Clinica
Executive Summary
Quintiles has invested £3m ($4.7m) in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients for personalised medicine applications.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"